Brief Introduction

Hunan Nucien Pharmaceutical, founded in December 2006, is an innovative pharmaceutical company focusing on the R & D, manufacturing and marketing of small molecule medicines. At present, the company has 34 product lines, 53 drug registration approvals and 8 API registration approvals, including 3 exclusive productsand 9 exclusive dosage forms or specifications. Itsmainproductsinclude antivirals、cardiovasculardrugs、antibiotics and other products. The company's class 1.1 innovative drug, peramivir sodium chloride injection, has been recognized by the market after several years of marketing, and nowenjoysa strong competitive edge for the treatment of influenza.

Company Overview

Full name Hunan Nucien Pharmaceutical Co., Ltd.
Abbreviations NUCIEN PHARMA
Code 688189
Founded 2006-12-27
Listing 2020-03-26
Domicile Hunan Province Changsha City
Website http://www.nucien.com/
Email nanxin@nucien.com
STAR Theme Biomedicine
CSRC Sector Manufacturing
Has weighted voting rights structure? No

Financials

Highlights

  2020 2019 2018
Earnings Per Share 1.01 0.87 0.51
R&D expenditure as a % of operating revenue 9.93% 7.08% 6.46%
Operating Revenue 1,088.12 1,014.22 700.52
Net Income 140.03 97.48 62.44

Income Statement (Unit: RMB mn)

  2020 2019 2018
Operating Revenue 1,088.12 1,014.22 700.52
Operating Costs 930.56 896.74 643.47
Operating Income 138.69 109.26 59.91
Pretax Income 141.17 110.64 63.97
Income Tax 1.14 13.16 1.53
Net Income 140.03 97.48 62.44

Balance Sheet(Unit: RMB mn)

  2020 2019 2018
Assets
Current Assets-Total 1,729.60 448.27 284.73
Non-current Assets-Total 373.38 370.45 411.32
Total Assets 2,102.97 818.72 696.05
Liabilities
Current Liabilities-Total 392.80 340.71 283.39
Non-current Liabilities-Total 85.27 120.75 147.85
Total Liabilities 478.07 461.45 431.23
Stockholder's Equity
Share Capital 1,449.82 314.53 307.75
Retained Profits 151.01 18.03 -73.45
Minority interests 24.08 24.70 30.52
Total Owners' Equity 1,624.91 357.27 264.82

Cash Flow Statement (Unit: RMB mn)

  2020 2019 2018
Net Cash Flows-Operating -290.84 32.56 64.41
Net Cash Flows-Investing -681.77 -12.80 -21.18
Net Cash Flows-Financing 1,117.34 9.82 6.86

Top 10 Shareholders

Name No. of Shares Held (mn) % of Shares Held
湖南湘投控股集团有限公司 40.00 28.57%
广州乾元投资管理企业(有限合伙) 22.00 15.71%
杭州鼎晖新趋势股权投资合伙企业(有限合伙) 15.00 10.71%
湖南湘江力远投资管理有限公司-湖南湘江大健康创业投资合伙企业(有限合伙) 5.00 3.57%
湖南省厚水投资合伙企业(有限合伙) 4.50 3.21%
杭州信为玺泰投资合伙企业(有限合伙) 4.50 3.21%
泉州市键宁银创投资有限公司 3.83 2.73%
叶胜利 2.74 1.95%
深圳市汇尚致鑫实业管理中心(有限合伙) 2.72 1.94%
中国工商银行股份有限公司-融通健康产业灵活配置混合型证券投资基金 2.00 1.43%
31 Mar 2021

Legal Statement

All information contained herein is provided by the underlying company itself and is for informational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. The Shanghai Stock Exchange does not guarantee its accuracy and reliability and shall under no circumstance be responsible or liable for any error or for any loss directly or indirectly arising from any inaccuracy or omission or from any decision, action or non-action based on or in reliance upon the information herein.

Users may view and download the information herein for personal and non-commercial use free of charge subject to the laws of the People's Republic of China and the Legal Statement. No part of the information herein may be copied, downloaded, stored in a retrieval system or transmitted in any form or by any means, rented, displayed, performed, reproduced, photocopied, altered, sold, broadcast, published or otherwise in whole or in part in any manner for commercial purposes, without the prior written consent of the Shanghai Stock Exchange.

Users are hereby reminded that the Legal Statement represents your legally binding agreement with the Shanghai Stock Exchange. By accessing or using this website, you are also signifying your agreement with and acceptance of all the contents in the Legal Statement. The Shanghai Stock Exchange reserves the right to amend and interpret the Legal Statement.